²ÝÁñÂÛ̳

Some examples of start-ups supported by PSL Valorisation

Whether it's the creation of start-ups based on breakthrough technologies, research contracts, framework agreements or licensing agreements with major groups, ETIs or SMEs, or joint initiatives with companies for training and research, PSL University has a wide range of models for commercialization. Recent examples include HifiBio, Safran, LightON and Toyota.

Spin-off from ESPCI Paris - PSL

, an ESPCI spin-off, identifies and characterizes antibodies for therapeutic use. Its combination of unique and innovative technologies enables very high throughput, single-cell screening of primary cells producing functional antibodies. The company's development program is underpinned by the revolution in microfluidic droplet technology, and strategic partnerships have been forged to develop new applications for the HiFiBiO platform.

MINES Paris - PSL - SAFRAN collaboration

The collaboration between is long-standing and fruitful; it concerns in particular components and structures operating at very high temperatures. It includes an experimental approach to the development of new materials, as well as numerical models for structural design and validation, and extends to multi-scale and multi-physics aspects.

Spin-off de l’Institut Langevin / ESPCI Paris - PSL & ENS - PSL

develops optical coprocessors for Artificial Intelligence (AI), addressing the challenges of scaling AI for widespread use, while minimizing its environmental impact. It is the result of a collaboration involving 3 PSL physics laboratories: Laboratoire Kastler-Brossel, Laboratoire de Physique Statistique, Institut Langevin, as well as independent researcher Igor Carron, now head of LightOn.LightOn has already won several awards, most recently the Grand Prix de l'Innovation de la Ville de Paris in the "digital technologies" category.

Stimunity, spin-off de l’Institut Curie

Stimunity develops bio-medicines that restore the immune system's defenses, enabling it to detect and then destroy cancer cells once more. The company was created following a fundamental discovery made by the Institut Curie's Innate Immunity laboratory, headed by Nicolas Manel, Inserm research director and co-founder of the start-up.Viruses have the ability to encapsulate a molecule that acts as a Trojan horse, activating the cell's immune system defenses. This discovery has been the subject of two major publications in the scientific journal Science. The creation of the start-up to develop the full potential of the patented technology was supported by the Institut Curie's development department. A licensing agreement was signed between Stimunity, INnserm and Institut Curie, along with a research partnership agreement between Stimunity and Nicolas Manel's laboratory.